Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma
NCT ID: NCT00000801
Last Updated: 2012-11-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
33 participants
INTERVENTIONAL
1998-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Combined modality therapy may prove of benefit for patients with AIDS-related primary CNS lymphoma.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients who upon staging workup are found to be without systemic involvement undergo one cycle of chemotherapy with cyclophosphamide, doxorubicin, vincristine, dexamethasone, and G-CSF. Cyclophosphamide, doxorubicin, and vincristine are administered intravenously on day 1. Dexamethasone is administered intravenously on day 1 and then orally thereafter with gradual discontinuation. G-CSF is administered subcutaneously daily beginning on day 2 and continuing for a total of 10 days or until blood counts have recovered to an acceptable level. Patients with evidence of cancer cells in their cerebrospinal fluid (CSF) will receive chemotherapy with intrathecal cytarabine twice weekly until no further evidence of cancer cells is found in the CSF, then once weekly for 6 weeks, and then monthly for 10 months. Seven to ten days following completion of one cycle of chemotherapy, patients undergo radiotherapy to the brain at a dose of 2.5 Gy daily for 5 days per week for approximately 4 weeks. Total dose to the whole brain and meninges is 30.0 Gy in 12 fractions, and total dose to the primary boost volume is 10.0 Gy in 4 fractions. During therapy, blood is drawn weekly and brain scans are performed every 3-12 weeks. An initial CSF sample will be obtained by lumbar puncture.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Filgrastim
Vincristine sulfate
Doxorubicin hydrochloride
Cyclophosphamide
Cytarabine
Dexamethasone
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* PCP prophylaxis with Bactrim, dapsone, or aerosolized pentamidine.
* Oral candidiasis prophylaxis with fluconazole, ketoconazole, or clotrimazole oral troches.
* Antiretroviral agent available by therapy IND.
* MAI prophylaxis with rifabutin (in patients with CD4 counts \< 100 cells/mm3).
Patients must have:
* HIV infection.
* Primary CNS lymphoma with NO systemic involvement.
Prior Medication:
Allowed:
* Prior corticosteroids.
Exclusion Criteria
Patients with the following symptoms or conditions are excluded:
* Concomitant malignancy other than Kaposi's sarcoma, curatively treated carcinoma in situ of the cervix, or squamous or basal cell carcinoma of the skin.
* Active uncontrolled infection.
* Renal failure, active nonmalignant duodenal ulcer, uncontrolled diabetes mellitus, or other serious medical conditions that would preclude aggressive cytotoxic chemotherapy administration.
* Active heart disease (congestive heart failure or heart block greater than first degree on EKG).
Concurrent Medication:
Excluded:
* Any investigational agent other than antiretroviral agents available by therapy IND.
Patients with the following prior conditions are excluded:
* No prior malignancy other than Kaposi's sarcoma, curatively treated carcinoma in situ of the cervix, or squamous cell or basal cell carcinoma of the skin.
* No new infectious complications within the past 2 weeks that require a change in antibiotics.
* History of myocardial infarction within the past 3 months.
Prior Medication:
Excluded:
* Prior chemotherapy other than for Kaposi's sarcoma.
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Krigel RL
Role: STUDY_CHAIR
Von Roenn J
Role: STUDY_CHAIR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
San Francisco AIDS Clinic / San Francisco Gen Hosp
San Francisco, California, United States
San Francisco Gen Hosp
San Francisco, California, United States
Univ of Colorado Health Sciences Ctr
Denver, Colorado, United States
Beth Israel Deaconess - West Campus
Boston, Massachusetts, United States
ECOG Data Management Office
Brookline, Massachusetts, United States
Mount Sinai Med Ctr
New York, New York, United States
Julio Arroyo
West Columbia, South Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Schultz C, Scott C, Sherman W, Donahue B, Fields J, Murray K, Fisher B, Abrams R, Meis-Kindblom J. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol. 1996 Feb;14(2):556-64. doi: 10.1200/JCO.1996.14.2.556.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ECOG E 1493
Identifier Type: -
Identifier Source: secondary_id
ACTG 252
Identifier Type: -
Identifier Source: org_study_id